SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Sjöstedt J.)
 

Search: WFRF:(Sjöstedt J.) > Modern Development ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003957naa a2200457 4500
001oai:DiVA.org:umu-187297
003SwePub
008210909s2021 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1872972 URI
024a https://doi.org/10.3390/pathogens100707952 DOI
040 a (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Conlan, J. Wayne4 aut
2451 0a Modern Development and Production of a New Live Attenuated Bacterial Vaccine, SCHU S4 Delta clpB, to Prevent Tularemia
264 c 2021-06-23
264 1b MDPI,c 2021
338 a electronic2 rdacarrier
520 a Inhalation of small numbers of Francisella tularensis subspecies tularensis (Ftt) in the form of small particle aerosols causes severe morbidity and mortality in people and many animal species. For this reason, Ftt was developed into a bona fide biological weapon by the USA, by the former USSR, and their respective allies during the previous century. Although such weapons were never deployed, the 9/11 attack quickly followed by the Amerithrax attack led the U.S. government to seek novel countermeasures against a select group of pathogens, including Ftt. Between 2005-2009, we pursued a novel live vaccine against Ftt by deleting putative virulence genes from a fully virulent strain of the pathogen, SCHU S4. These mutants were screened in a mouse model, in which the vaccine candidates were first administered intradermally (ID) to determine their degree of attenuation. Subsequently, mice that survived a high dose ID inoculation were challenged by aerosol or intranasally (IN) with virulent strains of Ftt. We used the current unlicensed live vaccine strain (LVS), first discovered over 70 years ago, as a comparator in the same model. After screening 60 mutants, we found only one, SCHU S4 Delta clpB, that outperformed LVS in the mouse ID vaccination-respiratory-challenge model. Currently, SCHU S4 Delta clpB has been manufactured under current good manufacturing practice conditions, and tested for safety and efficacy in mice, rats, and macaques. The steps necessary for advancing SCHU S4 Delta clpB to this late stage of development are detailed herein. These include developing a body of data supporting the attenuation of SCHU S4 Delta clpB to a degree sufficient for removal from the U.S. Select Agent list and for human use; optimizing SCHU S4 Delta clpB vaccine production, scale up, and long-term storage; and developing appropriate quality control testing approaches.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Mikrobiologi inom det medicinska området0 (SwePub)301092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Microbiology in the medical area0 (SwePub)301092 hsv//eng
653 a tularemia
653 a Francisella tularensis
653 a live attenuated vaccine
653 a product development
700a Sjöstedt, Andersu Umeå universitet,Molekylär Infektionsmedicin, Sverige (MIMS),Institutionen för klinisk mikrobiologi4 aut0 (Swepub:umu)ansj0004
700a Gelhaus, H. Carl4 aut
700a Fleming, Perry4 aut
700a McRae, Kevan4 aut
700a Cobb, Ronald R.4 aut
700a De Pascalis, Roberto4 aut
700a Elkins, Karen L.4 aut
710a Umeå universitetb Molekylär Infektionsmedicin, Sverige (MIMS)4 org
773t Pathogensd : MDPIg 10:7q 10:7x 2076-0817
856u https://doi.org/10.3390/pathogens10070795y Fulltext
856u https://umu.diva-portal.org/smash/get/diva2:1592463/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
856u http://umu.diva-portal.org/smash/get/diva2:1592463/FULLTEXT01
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-187297
8564 8u https://doi.org/10.3390/pathogens10070795

Find in a library

  • Pathogens (Search for host publication in LIBRIS)

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view